HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nakayama, K. Articles by Kitamura, M. Search for Related Content PubMed PubMed Citation Articles by Nakayama, K. Articles by Kitamura, M.

Unexpected Transcriptional Induction of Monocyte Chemoattractant Protein 1 by Proteasome Inhibition: Involvement of the c-Jun N-Terminal Kinase-Activator Protein 1 Pathway¹

Department of Medicine, Royal Free and University College Medical School, University College London, Jules Thorn Institute, Middlesex Hospital, London, United Kingdom

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Proteasome inhibitors, the well-known inhibitors of NF-B, are recently considered therapeutic agents for inflammation. However, the anti-inflammatory properties of these agents have not been fully evaluated. In this report we describe a novel effect of proteasome inhibitors on the expression of monocyte chemoattractant protein 1 (MCP-1) in mesangial cells. We found that proteasome inhibitor MG132 dose-dependently induced expression of MCP-1 at the transcriptional level. The stimulatory effect was similarly observed with other proteasome inhibitors (proteasome inhibitor 1 and lactacystin) and in other cell types (NRK fibroblasts). The 5'-flanking region of the MCP-1 gene contains multiple AP-1 sites. To explore the mechanisms involved, we examined the effects of proteasome inhibition on the AP-1 pathway. Northern blot analysis showed that MG132 rapidly induced the expression of c-jun, but not c-fos. Immunoblot analysis showed that MG132 prevented degradation of c-Jun protein. Kinase assay revealed that c-Jun N-terminal kinase (JNK) was rapidly activated by MG132. Consistent with these results, a reporter assay showed that AP-1 activity was up-regulated after treatment with MG132. Curcumin, a pharmacological inhibitor of the JNK-AP-1 pathway, abrogated the induction of MCP-1 by MG132. Similarly, stable transfection with a dominant-negative mutant of c-Jun attenuated both MG132-induced activation of AP-1 and expression of MCP-1. The transcriptional activation by proteasome inhibitors was observed not only in MCP-1, but also in other AP-1-dependent genes, including stromelysin and mitogen-activated protein kinase phosphatase 1. These data revealed that proteasome inhibition triggered the expression of MCP-1 and other genes via the multistep induction of the JNK-c-Jun/AP-1 pathway.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
The ubiquitin/proteasome system is the major pathway for selective protein degradation in eukaryotic cells. Degradation of proteins by this system occurs via two successive steps. First, the target proteins are conjugated to the polypeptide ubiquitin, and then the ubiquitin-conjugated proteins are recognized by the proteasome, leading to degradation. The ubiquitin/proteasome system targets both short-lived, normal proteins and misfolded, abnormal proteins (1).

Recent investigations have disclosed vital roles of this system in signal transduction processes. It is because various signaling molecules are degraded via the ubiquitin/proteasome pathway. The target molecules include cell cycle proteins (cyclins and cyclin-dependent kinase inhibitors), transcriptional regulators (IBs, activating transcription factor-2, hypoxia-inducible factor-1, and c-Fos), and proapoptotic proteins (p53 and Bax) (2). Because of this, proteasome inhibitors have been used as useful tools in cell biology to modulate cell proliferation, gene regulation, and apoptosis (1, 2, 3). In particular, proteasome inhibitors have been widely used as inhibitors of NF-B. It is based on the facts that these agents block both degradation of IBs and processing of p105 to the major NF-B component p50 (4, 5). Treatment of cells with proteasome inhibitors dramatically suppresses expression of NF-B-dependent genes, including monocyte chemoattractant protein 1 (MCP-1)³ (6). Because NF-B regulates various inflammatory genes, proteasome inhibitors are currently considered therapeutic agents for inflammation (7, 8).

MCP-1 is a member of the chemokine family and specifically attracts monocytes (9). In response to stimuli, MCP-1 is ubiquitously produced by various cell types, including resident glomerular cells (9, 10, 11). In glomerulonephritis, infiltration of monocytes/macrophages is a common pathologic feature (12). Expression of MCP-1 is observed in the mesangium of inflamed glomeruli (13, 14, 15), and MCP-1 produced by mesangial cells plays a crucial role in macrophage attraction during glomerular inflammation (16). In mesangial cells, expression of MCP-1 in response to various stimuli is regulated by NF-B (17, 18, 19, 20, 21). However, we recently found that MCP-1 expression was paradoxically induced by proteasome inhibitors in unstimulated mesangial cells. The present study was performed to investigate the mechanisms involved in this unexpected finding.

In this report, we describe a novel role of the proteasome system in the regulation of MCP-1 expression. Our results show that proteasome inhibition rapidly induces the expression of c-jun, inhibits degradation of c-Jun protein, and triggers phosphorylation of c-Jun N-terminal kinase (JNK), leading to activation of AP-1 and consequent induction of MCP-1 in mesangial cells.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Cells and transfectants

Rat mesangial cells (SM43) were established from isolated glomeruli of a male Sprague Dawley rat and identified as being of the mesangial cell phenotype as described previously (22). The rat fibroblast cell line NRK49F was purchased from American Type Culture Collection (Manassas, VA). Cells were maintained in DMEM/Ham’s F-12 (Life Technologies, Gaithersburg, MD) supplemented with 100 U/ml penicillin G, 100 µg/ml streptomycin, 0.25 µg/ml amphotericin B, and 10% FCS. Medium containing 0.5% FCS was generally used for experiments.

SM/JUNDN1 cells in which AP-1 is selectively inactivated were established by stable transfection of SM43 with a dominant-negative mutant of c-Jun, TAM-67 (23). SM/JUNDN1 cells exhibit attenuated activity of AP-1 under both unstimulated and stimulated conditions (23). As a control, mock-transfected SM/Neo cells that express neo alone were used (24).

Pharmacologic manipulations

Confluent cells were treated with proteasome inhibitor MG132 (1–50 µM; Peptide Institute, Osaka, Japan), proteasome inhibitor 1 (PSI-1; 50 µM; Calbiochem-Novabiochem, Nottingham, U.K.), or lactacystin (25 µM; Peptide Institute, Osaka, Japan) for 1–24 h. To examine the effects of MG132 on the inducible expression of MCP-1, cells were pretreated with or without MG132 (25 µM) for 1 h and stimulated by human recombinant IL-1 (5 ng/ml; Otsuka Pharmaceutical, Tokushima, Japan) for 8 h. To examine the effects of the c-Jun/AP-1 inhibitor curcumin and the RNA synthesis inhibitor actinomycin D, cells were pretreated with curcumin (20 µM; Sigma-Aldrich, Poole, U.K.) or actinomycin D (500 ng/ml; Serva, Heidelberg, Germany) for 1 h and stimulated with MG132. The concentrations used are sufficient to inhibit the c-Jun/AP-1 pathway and RNA synthesis in SM43 mesangial cells (25, 26). After the treatments, cells were harvested and subjected to Northern blot analysis as follows.

Northern blot analysis

Total RNA was extracted by the single-step method (27) and subjected to analyses as described previously (28). As probes, mouse JE/MCP-1 cDNA (29), human c-fos cDNA (30), human c-jun cDNA (30), rat stromelysin cDNA (31), human mitogen-activated protein (MAP) kinase phosphatase 1 (MKP-1) cDNA (32), and rat GAPDH cDNA were labeled with [³²P]dCTP using the random priming method and used for hybridization.

Western blot analysis

Confluent mesangial cells were treated with MG132 (50 µM) for up to 24 h. After the treatment cells were lysed with sample buffer (2% SDS, 5% glycerol, 0.003% bromphenol blue, and 1% 2-ME in 125 mM Tris-HCl, pH 6.8) and subjected to Western blot analysis using an anti-MCP-1 Ab (Genzyme, Cambridge, MA) as described previously (28). To examine an effect of MG132 on the stability of c-Jun protein, cells were first treated with MG132 for 12 h to allow for accumulation of c-Jun. The cells were then washed three times and incubated with or without MG132 (50 µM) for 8 h in the presence or the absence of protein synthesis inhibitor cycloheximide (50 µM; Sigma). After the treatment, cells were subjected to Western blot analysis using an anti-c-Jun Ab (New England Biolabs, Hertfordshire, U.K.). The experiment was repeated three times, and relative protein levels were evaluated by densitometric analysis.

Kinase assay

Mesangial cells were treated with MG132 (50 µM) for 1–6 h and subjected to JNK assays using the SAPK/JNK Assay kit (New England Biolabs) and PhosphoPlus SAPK/JNK (Thr¹⁸²/Tyr¹⁸⁵) Ab kit (Cell Signaling Technology, Beverly, MA) (33, 34). JNK activity was evaluated by site-specific phosphorylation of c-Jun and JNK following protocols provided by the manufacturers.

Reporter assay

The activity of AP-1 was assessed by transient transfection (34). In brief, using the calcium phosphate coprecipitation method, mesangial cells cultured in 24-well plates (1.0 x 10⁵/well) were transfected with a reporter plasmid pTRE-LacZ (a gift from Dr. A. S. Alberts, Imperial Cancer Research Fund, London, U.K.) (35) or a control plasmid pCI-gal (a gift from Promega, Madison, WI) at 0.33 µg/well, respectively. pTRE-LacZ introduces a -galactosidase gene (lacZ) under control of 12-O-tetradecanoylphorbol-13-acetate response elements (TREs). pCI-gal introduces lacZ under control of the immediate-early enhancer/promoter of human CMV. After transfection, cells were incubated for 48 h in 0.5% FCS, stimulated with MG132 (10–25 µM) for 24 h, and subjected to 5-bromo-4-chloro-3-indolyl--D-galactopyranoside (X-gal) assay (36). Activity of AP-1 was evaluated by counting X-gal-positive cells in each well. The number of X-gal-positive cells transfected with pTRE-LacZ was normalized by the number of positive cells transfected with the control plasmid pCI-gal, and relative percentages were calculated. Assays were performed in quadruplicate.

Statistical analysis

Data were expressed as the mean ± SD. Statistical analysis was performed using ANOVA to compare data in different groups. A p < 0.05 was used to indicate a statistically significant difference. All experiments were repeated twice or three times, and representative data were demonstrated.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Induction of MCP-1 expression by proteasome inhibition

In mesangial cells expression of MCP-1 in response to various stimuli is regulated by NF-B (17, 18, 19, 20, 21). We examined the effects of proteasome inhibitors, the well-known NF-B inhibitors, on the constitutive and IL-1-inducible expression of MCP-1. Rat mesangial cells were pretreated with or without MG132 and incubated in the presence or the absence of IL-1. Northern blot analysis showed that, as expected, MG132 dramatically suppressed the induction of MCP-1 by IL-1. However, unexpectedly, MG132 increased the steady-state level of MCP-1 mRNA under the unstimulated condition (Fig. 1A). This effect was observed at concentrations >25 µM (Fig. 1B) and with incubation for >8–12 h (Fig. 1C). Consistent with the increase in the mRNA level, MCP-1 protein was also induced in MG132-treated cells (Fig. 1D). A similar stimulatory effect was observed with different types of proteasome inhibitors, PSI-1 and lactacystin (Fig. 1E), and in other cell type NRK49F fibroblasts (Fig. 1F).

View larger version (47K): [in this window] [in a new window]   FIGURE 1. Up-regulation of MCP-1 mRNA and protein by proteasome inhibition. A, Effects of MG132 on the constitutive and IL-1-inducible expression of MCP-1. Rat mesangial cells were pretreated with (+) or without (-) MG132 (25 µM) for 1 h, incubated in the presence (+) or the absence (-) of IL-1 (5 ng/ml) for 8 h, and subjected to Northern blot analysis. Expression of GAPDH is shown as a loading control. B and C, Dose- and time-dependent effects of MG132. Mesangial cells were incubated with 1–50 µM MG132 for 8 h (B) or with MG132 (50 µM) for 2–12 h (C), and Northern blot analysis was performed. D, Effect of MG132 on the level of MCP-1 protein. Mesangial cells were treated with MG132 (50 µM) for up to 24 h, and Western blot analysis was performed. E, Effects of other proteasome inhibitors. Mesangial cells were treated with or without PSI-1 (50 µM) or lactacystin (Lacta; 25 µM) for 8–12 h and subjected to Northern blot analysis. F, Effect of MG132 in other cell type. NRK49F rat fibroblasts were treated with or without MG132 (50 µM) for 8 h, and Northern blot analysis was performed.

View larger version (29K): [in this window] [in a new window]   FIGURE 2. Effect of actinomycin D on the proteasome inhibitor-induced increase in MCP-1 mRNA. Mesangial cells were pretreated with (+) or without (-) actinomycin D (500 ng/ml) for 1 h and stimulated with (+) or without (-) MG132 (25 µM) for 12 h. The expression level of MCP-1 was examined by Northern blot analysis. Data from both short exposure (short exp) and long exposure (long exp) to films are shown.

The 5'-flanking region of the MCP-1 gene contains multiple NF-B sites and AP-1 sites (37, 38). It suggests potential roles of NF-B and AP-1 in the regulation of MCP-1 expression. Because proteasome inhibitors are well-known NF-B inhibitors, we speculated that proteasome inhibition may induce MCP-1 expression via activation of AP-1. To examine this possibility, mesangial cells were treated with MG132 for up to 12 h, and expression of c-jun and c-fos was examined. Northern blot analysis showed that the expression of c-jun was induced within 2 h and peaked to maximum at 4 h (Fig. 3A). The increased expression of c-jun was sustained for at least 12 h. In contrast, induction of c-fos was not detectable in MG132-treated cells.

View larger version (42K): [in this window] [in a new window]   FIGURE 3. Induction and activation of the JNK-c-Jun/AP-1 pathway by proteasome inhibition. A, Selective induction of c-jun, but not c-fos, by proteasome inhibition. Mesangial cells were treated with MG132 (50 µM) for 2–12 h and subjected to Northern blot analysis. B, Suppression of c-Jun degradation by proteasome inhibition. Mesangial cells were treated with MG132 (50 µM) for 12 h to allow for accumulation of c-Jun protein. The cells were then washed and incubated with (+) or without (-) MG132 for 8 h in the presence (+) or the absence (-) of the protein synthesis inhibitor cycloheximide (CHX; 50 µM). Extracted protein was subjected to Western blot analysis of c-Jun. The experiment was repeated three times, and relative protein levels were evaluated by densitometric analysis (bottom; mean ± SD, percentage). C, JNK activation by proteasome inhibition. Mesangial cells were treated with MG132 (50 µM) for 1–6 h and subjected to JNK assay. c-Jun protein is shown as a loading control. D, Activation of AP-1 by proteasome inhibition. Mesangial cells were transfected with an AP-1 reporter plasmid pTRE-LacZ or a control plasmid pCI-gal. After the transfection, cells were stimulated with MG132 (10–25 µM) for 24 h and subjected to X-gal assay. Activity of AP-1 was evaluated as described in Materials and Methods. Assays were performed in quadruplicate. Data are shown as the mean ± SD. *, p < 0.05 vs untreated;**, p < 0.05 vs both untreated and 10 µM MG132 treated.

JNK is known to be the crucial, upstream activator of c-Jun/AP-1. The effect of MG132 on the JNK activity was also tested using c-Jun protein as a substrate. Kinase assay showed that the JNK-mediated phosphorylation of c-Jun at Ser⁶³, a site important for c-Jun-dependent transcriptional activity, was induced within 1 h and peaked to a maximum after 3 h (Fig. 3C). Sustained activation of JNK was observed for at least 6 h. Consistently, phosphorylation of JNK at Thr¹⁸²/Tyr¹⁸⁵ was also observed after the treatment with MG132 (data not shown).

To further confirm that the JNK-c-Jun/AP-1 pathway is indeed activated by proteasome inhibition, a reporter assay was performed. Mesangial cells were transiently transfected with a control plasmid or an AP-1 reporter plasmid, treated with or without MG132, and subjected to X-gal assay. In the control transfection, the number of -gal-positive cells was modestly decreased by treatment with MG132 (813 ± 48 cells/well in untreated, 730 ± 23 cells/well in 10 µM, and 624 ± 20 cells/well in 25 µM). In contrast, the number of -gal-positive cells was significantly increased by MG132 in the cells transfected with the AP-1 reporter plasmid (53 ± 8 cells/well in untreated, 79 ± 5 cells/well in 10 µM, and 91 ± 7 cells/well in 25 µM). The normalized, relative activity of AP-1 was significantly increased by the treatment with MG132 to 169 ± 11% in 10 µM-treated cells and to 228 ± 18% in 25 µM-treated cells (p < 0.05; Fig. 3D).

Role of the c-Jun/AP-1 pathway in proteasome inhibitor-triggered MCP-1 expression

To examine whether the activation of AP-1 is responsible for the proteasome inhibitor-triggered MCP-1 expression, mesangial cells were pretreated with c-Jun/AP-1 inhibitor curcumin and stimulated by MG132. Northern blot analysis showed that induction of MCP-1 by MG132 was abolished by treatment with curcumin (Fig. 4A).

View larger version (23K): [in this window] [in a new window]   FIGURE 4. Role of the c-Jun/AP-1 pathway in the proteasome inhibitor-triggered MCP-1 expression. A, Effect of c-Jun/AP-1 inhibitor curcumin. Mesangial cells were pretreated with (+) or without (-) curcumin (20 µM) for 1 h, stimulated with (+) or without (-) MG132 (25 µM) for 12 h, and subjected to Northern blot analysis. B, Activity of AP-1 in control cells and AP-1-inactive cells treated with proteasome inhibitor. Control mesangial cells (SM/Neo) and mesangial cells stably expressing a dominant-negative mutant of c-jun (SM/JUNDN1) were transfected with pTRE-LacZ or pCI-gal. After the transfection, cells were treated with (+) or without (-) MG132 (25 µM) for 24 h and subjected to X-gal assay. Assays were performed in quadruplicate. Data are shown as the mean ± SD. *, p < 0.05. C, Expression of MCP-1 in control cells and AP-1-inactive cells treated with proteasome inhibitor. SM/Neo cells and SM/JUNDN1 cells were treated with or without MG132 (50 µM) for 8 h, and Northern blot analysis was performed.

Effect of proteasome inhibition on the expression of other AP-1-dependent genes

As demonstrated above, proteasome inhibitors activate the c-Jun/AP-1 pathway. It is reasonable to speculate that proteasome inhibition induces not only MCP-1, but also other AP-1-dependent genes. Indeed, the AP-1-dependent gene, c-jun, was induced after treatment with MG132 (Fig. 3A). To further examine this possibility, we tested the expression of other AP-1-dependent genes, stromelysin and MKP-1.

Stromelysin is a member of the family of matrix metalloproteinases. The 5'-flanking region of the stromelysin gene contains TRE, the binding site of AP-1 (40). We previously showed that induction of stromelysin in response to IL-1 and pyrrolidine dithiocarbamate is regulated by AP-1 in mesangial cells (23, 25). MKP-1 is a prototypic member of the family of inducible dual specificity phosphatases. The regulatory region of the MKP-1 gene contains TRE (41), and activation of JNK induces expression of MKP-1 mRNA (42), suggesting a role for AP-1 in the regulation of MKP-1.

Mesangial cells were treated with three different proteasome inhibitors, MG132, PSI-1, and lactacystin, and expression of stromelysin and MKP-1 was examined by Northern blot analysis. Consistent with the results with MCP-1, expression of stromelysin was substantially induced after treatment with all three proteasome inhibitors (Fig. 5A). Similar stimulatory effects were observed in the expression of MKP-1 (Fig. 5B).

View larger version (51K): [in this window] [in a new window]   FIGURE 5. Effect of proteasome inhibition on the expression of other AP-1-dependent genes. Mesangial cells were treated with (+) or without (-) MG132 (25 µM), PSI-1 (50 µM), or lactacystin (Lacta; 25 µM) for 8–12 h and subjected to Northern blot analysis of stromelysin and MKP-1.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

In this report, we demonstrated that after treatment with MG132, the stability of the c-Jun protein was increased. This result is consistent with a previous report showing that degradation of c-Jun was proteasome dependent (43). However, our results also showed that expression of c-jun mRNA was rapidly and selectively induced after proteasome inhibition. Although the proteasome system may affect the stability of certain mRNAs (44), our data indicated that the increased c-jun level was due to de novo transcription (our unpublished observation). It suggested that proteasome inhibition induced c-Jun protein via both transcriptional and posttranslational mechanisms. In contrast to the dramatic induction of c-jun, the expression of c-fos was not induced by proteasome inhibitors. This may be due to the fact that the expression of c-jun, but not c-fos, is regulated predominantly by AP-1 (45).

Another important finding is that activation of JNK, the selective upstream activator of c-Jun/AP-1, was rapidly induced after proteasome inhibition. Currently, it is not known how proteasome inhibition activates JNK. One possibility may be that the proteasome system participates in constitutive degradation of short-lived, upstream molecules that are crucial for activation of JNK. Another mechanism might be that inhibitors of JNK are down-regulated by proteasome inhibition. Some reports showed that other members of the MAP kinase family may also be activated by proteasome inhibitors (46, 47), and suppression of common inhibitors of MAP kinases, e.g., MAP kinase phosphatases, might be involved in the activation of JNK. However, our current results showed that MKP-1, the prototypic MAP kinase phosphatase, was, rather, up-regulated by proteasome inhibition.

Previous reports showed that the 5'-flanking region of the MCP-1 gene contains NF-B sites and AP-1 sites (37, 38). The majority of previous data emphasized the importance of NF-B, but not AP-1, in the induction of MCP-1. For example, in mesangial cells, induction of MCP-1 by various stimuli is NF-B dependent (17, 18, 19, 20, 21) and AP-1 independent (48). In contrast, the present data showed the critical role of AP-1 in the regulation of MCP-1, i.e., MCP-1 can be induced via the AP-1-dependent, NF-B-independent mechanism. It is consistent with our recent finding that retinoic acid suppressed basal expression of MCP-1 via intervention in the AP-1-dependent, NF-B-independent pathway (26).

In this investigation, we focused on the importance of AP-1 in the induction of MCP-1 and other genes by proteasome inhibition. However, proteasome regulates the degradation of various other proteins. The effect of proteasome inhibitors observed here might be mediated by stabilization of other signaling molecules. For example, it has been reported that Sp-1 is degraded by the proteasome system (49) and that its binding sites are present in the promoter regions of MCP-1 and MKP-1 genes (41, 50). We cannot exclude the possibility that the induction of these genes by proteasome inhibition could be mediated in part by stabilization of other transcription factors, including Sp-1.

Proteasome inhibitors have been considered therapeutic drugs for the treatment of malignant diseases. This is mainly due to the fact that these agents induce apoptosis of rapidly dividing tumor cells but inhibit apoptosis of normal, nondividing cells (2). Another potential, therapeutic target of proteasome inhibitors is inflammation. At inflammatory sites, various molecules, including cytokines/chemokines and leukocyte adhesion molecules, are expressed via NF-B-dependent mechanisms (51). Because proteasome inhibitors suppress the activation of NF-B, it is not surprising that these agents have anti-inflammatory properties. However, it should be noted that proteasome inhibitors also have the potential for activating AP-1, the crucial component involved in cell proliferation, apoptosis, and expression of inflammatory mediators (28, 34, 52). This pharmacologic property could limit the utility of these agents as therapeutic drugs in some situations. Of note, a recent report showed that proteasome inhibition caused a proinflammatory response in neural cells (53).

In summary, the present data elucidated the novel potential of proteasome inhibitors as dual regulators of MCP-1. To our knowledge, this is the first study to demonstrate the importance of the proteasome system in the suppression of MCP-1 in unstimulated cells.

	Footnotes

 
¹ This work was supported in part by grants from Wellcome Trust and National Kidney Research Fund (to M.K.).

² Address correspondence and reprint requests to Dr. Masanori Kitamura, Department of Medicine, University College Medical School, University College London, Jules Thorn Institute (7th Floor), Middlesex Hospital, Mortimer Street, London, WIT 3AA, U.K. E-mail address: m.kitamura{at}ucl.ac.uk

³ Abbreviations used in this paper: MCP-1, monocyte chemoattractant protein 1; PSI-1, proteasome inhibitor 1; JNK, c-Jun N-terminal kinase; MAP, mitogen-activated protein; MKP-1, MAP kinase phosphatase 1; TRE, 12-O-tetradecanoylphorbol-13-acetate response element; X-gal, 5-bromo-4-chloro-3-indolyl--D-galactopyranoside.

Received for publication October 31, 2000. Accepted for publication May 7, 2001.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Kornitzer, D., A. Ciechanover. 2000. Modes of regulation of ubiquitin-mediated protein degradation. J. Cell. Physiol. 182:1.[Medline]
2. Lee, D. H., A. L. Goldberg. 1998. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 8:397.[Medline]
3. Ciechanover, A.. 1998. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J. 17:7151.[Medline]
4. Hellerbrand, C., C. Jobin, Y. Iimuro, L. Licato, R. B. Sartor, D. A. Brenner. 1998. Inhibition of NF-B in activated rat hepatic stellate cells by proteasome inhibitors and an IB super-repressor. Hepatology 27:1285.[Medline]
5. Palombella, V. J., O. J. Rando, A. L. Goldberg, T. Maniatis. 1994. The ubiquitin-proteasome pathway is required for processing the NF-B1 precursor protein and the activation of NF-B. Cell 78:773.[Medline]
6. Parry, G. C., T. Martin, K. A. Felts, R. R. Cobb. 1998. IL-1-induced monocyte chemoattractant protein-1 gene expression in endothelial cells is blocked by proteasome inhibitors. Arterioscler. Thromb. Vasc. Biol. 18:934.[Abstract/Free Full Text]
7. Meng, L., R. Mohan, B. H. B. Kwok, M. Elofsson, N. Sin, C. M. Crews. 1999. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. USA 96:10403.[Abstract/Free Full Text]
8. Palombella, V. J., E. M. Conner, J. W. Fuseler, A. Destree, J. M. Davis, F. S. Laroux, R. E. Wolf, J. Huang, S. Brand, P. J. Elliott, et al 1998. Role of the proteasome and NF-B in streptococcal cell wall-induced polyarthritis. Proc. Natl. Acad. Sci. USA 95:15671.[Abstract/Free Full Text]
9. Leonard, E. J., T. Yoshimura. 1990. Human monocyte chemoattractant protein-1 (MCP-1). Immunol. Today 11:97.[Medline]
10. Zoja, C., J. M. Wang, S. Bettoni, M. Sironi, D. Renzi, F. Chiaffarino, H. E. Abboud, J. Van-Damme, A. Mantovani, G. Remuzzi. 1991. Interleukin-1 and tumor necrosis factor- induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells. Am. J. Pathol. 138:991.[Abstract]
11. Rovin, B. H., T. Yoshiumura, L. Tan. 1992. Cytokine-induced production of monocyte chemoattractant protein-1 by cultured human mesangial cells. J. Immunol. 148:2148.[Abstract]
12. Main, I. W., D. J. Nikolic-Paterson, R. C. Atkins.. 1992. T cells and macrophages and their role in renal injury. Semin. Nephrol. 12:395.[Medline]
13. Stahl, R. A. K., F. Thaiss, M. Disser, U. Helmchen, K. Hora, D. Schlondorff. 1993. Increased expression of monocyte chemoattractant protein-1 in anti-thymocyte antibody-induced glomerulonephritis. Kidney Int. 44:1036.[Medline]
14. Rovin, B. H., M. Rumancik, L. Tan, J. Dickerson. 1994. Glomerular expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis. Lab. Invest. 71:536.[Medline]
15. Neugarten, J., G. W. Feith, K. J. M. Assmann, Z. Shan, E. R. Stanley, D. Schlondorff. 1995. Role of macrophages and colony-stimulating factor-1 in murine antiglomerular basement membrane glomerulonephritis. J. Am. Soc. Nephrol. 5:1903.[Abstract/Free Full Text]
16. Tang, W. W., M. Qi, J. S. Warren. 1996. Monocyte chemoattractant protein 1 mediates glomerular macrophage infiltration in anti-GBM Ab GN. Kidney Int. 50:665.[Medline]
17. Rovin, B. H., J. A. Dickerson, L. C. Tan, C. A. Hebert. 1995. Activation of nuclear factor-B correlates with MCP-1 expression by human mesangial cells. Kidney Int. 48:1263.[Medline]
18. Duque, N., C. Gomez-Guerrero, J. Egido. 1997. Interaction of IgA with Fc receptors of human mesangial cells activates transcription factor nuclear factor-B and induces expression and synthesis of monocyte chemoattractant protein-1, IL-8, and IFN-inducible protein 10. J. Immunol. 159:3474.[Abstract]
19. Ruiz-Ortega, M., C. Bustos, M. A. Hernandez-Presa, O. Lorenzo, J. J. Plaza, J. Egido. 1998. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-B activation and monocyte chemoattractant protein-1 synthesis. J. Immunol. 161:430.[Abstract/Free Full Text]
20. Ruiz-Ortega, M., O. Lorenzo, J. Egido. 2000. Angiotensin III increases MCP-1 and activates NF-B and AP-1 in cultured mesangial and mononuclear cells. Kidney Int. 57:2285.[Medline]
21. Hisada, Y., H. Sakurai, T. Sugaya. 2000. Cell to cell interaction between mesangial cells and macrophages induces the expression of monocyte chemoattractant protein-1 through nuclear factor-B activation. Biochem. Biophys. Res. Commun. 269:309.[Medline]
22. Kitamura, M., S. Taylor, R. Unwin, S. Burton, F. Shimizu, L. G. Fine. 1994. Gene transfer into the rat renal glomerulus via a mesangial cell vector: site-specific delivery, in situ amplification, and sustained expression of an exogenous gene in vivo. J. Clin. Invest. 94:497.
23. Yokoo, T., M. Kitamura. 1996. Opposite, binary regulatory pathways involved in IL-1-mediated stromelysin gene expression in rat mesangial cells. Kidney Int. 50:894.[Medline]
24. Yokoo, T., M. Kitamura. 1996. Dual regulation of IL-1-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-B and AP-1. Am. J. Physiol. 270:F123.[Abstract/Free Full Text]
25. Yokoo, T., M. Kitamura. 1996. Antioxidant PDTC induces stromelysin expression in mesangial cells via a tyrosine kinase-AP-1 pathway. Am. J. Physiol. 270:F806.[Abstract/Free Full Text]
26. Lucio-Cazana, J., K. Nakayama, Q. Xu, T. Konta, V. Moreno-Manzano, A. Furusu, M. Kitamura. 2001. Suppression of constitutive but not IL-1-inducible expression of monocyte chemoattractant protein-1 in mesangial cells by retinoic acids: intervention in the activator protein-1 pathway. J. Am. Soc. Nephrol. 12:668.
27. Chomczynski, P., N. Sacchi. 1987. Single-step method of RNA isolation by acid-guanidinum thiocyanate-phenol chloroform extraction. Anal. Biochem. 162:156.[Medline]
28. Kitamura, M.. 1997. Identification of an inhibitor targeting macrophage production of monocyte chemoattractant protein-1 as TGF-1. J. Immunol. 159:1404.[Abstract]
29. Rollins, B. J., E. D. Morrison, C. D. Stiles. 1988. Cloning and expression of JE, a gene inducible by platelet-derived growth factor and whose product has cytokine-like properties. Proc. Natl. Acad. Sci. USA 85:3738.[Abstract/Free Full Text]
30. McDonnell, S. E., L. D. Kerr, L. M. Matrisian. 1990. Epidermal growth factor stimulation of stromelysin mRNA in rat fibroblast requires induction of proto-oncogenes c-fos and c-jun and activation of protein kinase C. Mol. Cell. Biol. 10:4284.[Abstract/Free Full Text]
31. Matrisian, L. M., G. T. Bowden, P. Krieg, G. Furstenberger, J. P. Briand, P. Leroy, R. Breathnach. 1986. The mRNA coding for the secreted protease transin is expressed more abundantly in malignant than benign tumors. Proc. Natl. Acad. Sci. USA 83:9413.[Abstract/Free Full Text]
32. Keyse, S. M., E. A. Emslie. 1992. Oxidative stress and heat shock induce a human gene encoding a protein-tyrosine phosphatase. Nature 359:644.[Medline]
33. Ishikawa, Y., M. Kitamura. 2000. Anti-apoptotic effect of quercetin: intervention in the JNK- and ERK-mediated apoptotic pathways. Kidney Int. 58:1078.[Medline]
34. Moreno-Manzano, V., Y. Ishikawa, J. Lucio-Cazana, M. Kitamura. 1999. Suppression of apoptosis by all-trans-retinoic acid: dual intervention in the c-Jun N-terminal kinase-AP-1 pathway. J. Biol. Chem. 274:20251.[Abstract/Free Full Text]
35. Meinkoth, J., A. S. Alberts, J. R. Feramisco. 1990. Construction of mammalian cell lines with indicator genes driven by regulated promoters. Ciba Found. Symp. 150:47.[Medline]
36. Kitamura, M., H. Kawachi. 1997. Creation of an in vivo cytosensor using engineered mesangial cells: automatic sensing of glomerular inflammation controls transgene activity. J. Clin. Invest. 100:1394.[Medline]
37. Rollins, B. J., P. Stier, T. Ernst, G. G. Wong. 1989. The human homolog of the JE gene encodes a monocyte secretory protein. Mol. Cell. Biol. 9:4687.[Abstract/Free Full Text]
38. Shyy, J. Y. J., Y. S. Li, P. E. Kolattukudy. 1990. Structure of human monocyte chemotactic protein gene and its regulation by TPA. Biochem. Biophys. Res. Commun. 169:346.[Medline]
39. Pendurthi, U., J. Williams, L. Rao. 1997. Inhibition of tissue factor gene activation in cultured endothelial cells by curcumin: suppression of activation of transcription factors Egr-1, AP-1, and NF-B. Arterioscler. Thromb. Vasc. Biol. 17:3406.[Abstract/Free Full Text]
40. Sato, H., M. Seiki. 1993. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8:395.[Medline]
41. Kwak, S. P., D. J. Hakes, K. J. Martell, J. E. Dixon. 1994. Isolation and characterization of a human dual specificity protein-tyrosine phosphatase gene. J. Biol. Chem. 269:3596.[Abstract/Free Full Text]
42. Bokemeyer, D., A. Sorokin, M. Yan, N. Ahn, D. Templeton, M. Dunn. 1996. Induction of mitogen-activated protein kinase phosphatase 1 by the stress-activated protein kinase signaling pathway but not by extracellular signal-regulated kinase in fibroblasts. J. Biol. Chem. 271:639.[Abstract/Free Full Text]
43. Treier, M., L. M. Staszewski, D. Bohmann. 1994. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the domain. Cell 78:787.[Medline]
44. Laroia, G., R. Cuesta, G. Brewer, R. J. Schneider. 1999. Control of mRNA decay by heat shock-ubiquitin-proteasome pathway. Science 284:499.[Abstract/Free Full Text]
45. Whitmarsh, A. J., R. J. Davis. 1996. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. 74:589.[Medline]
46. Merrin, A. B., V. L. Gabai, J. Yaglom, V. I. Shifrin, M. Y. Sherman. 1998. Proteasome inhibitors activates stress kinases and induce Hsp72: diverse effects on apoptosis. J. Biol. Chem. 273:6373.[Abstract/Free Full Text]
47. Hashimoto, K., G. Guroff, Y. Katagiri. 2000. Delayed and sustained activation of p42/p44 mitogen-activated protein kinase induced by proteasome inhibitors through p21^ras in PC12 cells. J. Neurochem. 74:92.[Medline]
48. Ishikawa, Y., H. Sugiyama, E. Stylianou, M. Kitamura. 1999. Bioflavonoid quercetin inhibits interleukin-1-induced transcriptional expression of monocyte chemoattractant protein-1 in glomerular cells via suppression of nuclear factor-B. J. Am. Soc. Nephrol. 10:2290.[Abstract/Free Full Text]
49. Su, K., X. Yang, M. Roos, A. Paterson, J. Kudlow. 2000. Human Sug1/p45 is involved in the proteasome-dependent degradation of Sp-1. Biochem. J. 348:281.
50. Ueda, A., K. Okuda, S. Ohno, A. Shirai, T. Igarashi, K. Matsunaga, J. Fukushima, S. Kawamoto, Y. Ishigatsubo, T. Okubo. 1994. NF-B and Sp-1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J. Immunol. 153:2052.[Abstract]
51. Baeuerle, P. A., T. Henkel. 1994. Function and activation of NF-B in the immune system. Annu. Rev. Immunol. 12:141.[Medline]
52. Curran, T., Jr B. R. Franza. 1988. Fos and Jun: the AP-1 connection. Cell 55:395.[Medline]
53. Rockwell, P., H. Yuan, R. Magnusson, M. E. Figueiredo-Pereira. 2000. Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE₂. Arch. Biochem. Biophys. 374:325.[Medline]

This article has been cited by other articles:

				S. Wolter, A. Doerrie, A. Weber, H. Schneider, E. Hoffmann, J. von der Ohe, L. Bakiri, E. F. Wagner, K. Resch, and M. Kracht c-Jun Controls Histone Modifications, NF-{kappa}B Recruitment, and RNA Polymerase II Function To Activate the ccl2 Gene Mol. Cell. Biol., July 1, 2008; 28(13): 4407 - 4423. [Abstract] [Full Text] [PDF]

				E. T. Efuet and K. Keyomarsi Farnesyl and Geranylgeranyl Transferase Inhibitors Induce G1 Arrest by Targeting the Proteasome Cancer Res., January 15, 2006; 66(2): 1040 - 1051. [Abstract] [Full Text] [PDF]

				J.-J. Chen, W.-C. Huang, and C.-C. Chen Transcriptional Regulation of Cyclooxygenase-2 in Response to Proteasome Inhibitors Involves Reactive Oxygen Species-mediated Signaling Pathway and Recruitment of CCAAT/Enhancer-binding Protein {delta} and CREB-binding Protein Mol. Biol. Cell, December 1, 2005; 16(12): 5579 - 5591. [Abstract] [Full Text] [PDF]

				K. A. Steinbrecher, W. Wilson III, P. C. Cogswell, and A. S. Baldwin Glycogen Synthase Kinase 3{beta} Functions To Specify Gene-Specific, NF-{kappa}B-Dependent Transcription Mol. Cell. Biol., October 1, 2005; 25(19): 8444 - 8455. [Abstract] [Full Text] [PDF]

				M. R. Tardif and M. J. Tremblay Tetraspanin CD81 Provides a Costimulatory Signal Resulting in Increased Human Immunodeficiency Virus Type 1 Gene Expression in Primary CD4+ T Lymphocytes through NF-{kappa}B, NFAT, and AP-1 Transduction Pathways J. Virol., April 1, 2005; 79(7): 4316 - 4328. [Abstract] [Full Text] [PDF]

				N. Sandbo, Y. Qin, S. Taurin, D. K. Hogarth, B. Kreutz, and N. O. Dulin Regulation of Serum Response Factor-Dependent Gene Expression by Proteasome Inhibitors Mol. Pharmacol., March 1, 2005; 67(3): 789 - 797. [Abstract] [Full Text] [PDF]

				J. D.-C. Arce, U. Soto, J. van Riggelen, E. Schwarz, H. z. Hausen, and F. Rosl Ectopic Expression of Nonliganded Retinoic Acid Receptor {beta} Abrogates AP-1 Activity by Selective Degradation of c-Jun in Cervical Carcinoma Cells J. Biol. Chem., October 29, 2004; 279(44): 45408 - 45416. [Abstract] [Full Text] [PDF]

				A. Gerber, A. Heimburg, A. Reisenauer, A. Wille, T. Welte, and F. Buhling Proteasome inhibitors modulate chemokine production in lung epithelial and monocytic cells Eur. Respir. J., July 1, 2004; 24(1): 40 - 48. [Abstract] [Full Text] [PDF]

				S. Balasubramanian and R. L. Eckert Green Tea Polyphenol and Curcumin Inversely Regulate Human Involucrin Promoter Activity via Opposing Effects on CCAAT/Enhancer-binding Protein Function J. Biol. Chem., June 4, 2004; 279(23): 24007 - 24014. [Abstract] [Full Text] [PDF]

				Y.-M. Chen, W.-C. Chiang, S.-L. Lin, K.-D. Wu, T.-J. Tsai, and B.-S. Hsieh Dual Regulation of Tumor Necrosis Factor-{alpha}-Induced CCL2/Monocyte Chemoattractant Protein-1 Expression in Vascular Smooth Muscle Cells by Nuclear Factor-{kappa}B and Activator Protein-1: Modulation by Type III Phosphodiesterase Inhibition J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 978 - 986. [Abstract] [Full Text] [PDF]

				P. G. Arndt, N. Suzuki, N. J. Avdi, K. C. Malcolm, and G. S. Worthen Lipopolysaccharide-induced c-Jun NH2-terminal Kinase Activation in Human Neutrophils: ROLE OF PHOSPHATIDYLINOSITOL 3-KINASE AND Syk-MEDIATED PATHWAYS J. Biol. Chem., March 19, 2004; 279(12): 10883 - 10891. [Abstract] [Full Text] [PDF]

				Y.-M. Chen, M.-I Hu-Tsai, S.-L. Lin, T.-J. Tsai, and B.-S. Hsieh Expression of CX3CL1/fractalkine by mesangial cells in vitro and in acute anti-Thy1 glomerulonephritis in rats Nephrol. Dial. Transplant., December 1, 2003; 18(12): 2505 - 2514. [Abstract] [Full Text] [PDF]

				B. McMorran, L. Town, E. Costelloe, J. Palmer, J. Engel, D. Hume, and B. Wainwright Effector ExoU from the Type III Secretion System Is an Important Modulator of Gene Expression in Lung Epithelial Cells in Response to Pseudomonas aeruginosa Infection Infect. Immun., October 1, 2003; 71(10): 6035 - 6044. [Abstract] [Full Text] [PDF]

				N. M. Dagia and D. J. Goetz A proteasome inhibitor reduces concurrent, sequential, and long-term IL-1{beta}- and TNF-{alpha}-induced ECAM expression and adhesion Am J Physiol Cell Physiol, October 1, 2003; 285(4): C813 - C822. [Abstract] [Full Text] [PDF]

				S. A. Stricker and T. L. Smythe Endoplasmic reticulum reorganizations and Ca2+ signaling in maturing and fertilized oocytes of marine protostome worms: the roles of MAPKs and MPF Development, July 1, 2003; 130(13): 2867 - 2879. [Abstract] [Full Text] [PDF]

				B. Drisaldi, R. S. Stewart, C. Adles, L. R. Stewart, E. Quaglio, E. Biasini, L. Fioriti, R. Chiesa, and D. A. Harris Mutant PrP Is Delayed in Its Exit from the Endoplasmic Reticulum, but Neither Wild-type nor Mutant PrP Undergoes Retrotranslocation Prior to Proteasomal Degradation J. Biol. Chem., June 6, 2003; 278(24): 21732 - 21743. [Abstract] [Full Text] [PDF]

				S. Sengul, C. Zwizinski, and V. Batuman Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells Am J Physiol Renal Physiol, June 1, 2003; 284(6): F1245 - F1254. [Abstract] [Full Text] [PDF]

				M.-J. Lee, C. W. Yang, D. C. Jin, Y. S. Chang, B. K. Bang, and Y.-S. Kim Bone Morphogenetic Protein-7 Inhibits Constitutive and Interleukin-1{beta}-Induced Monocyte Chemoattractant Protein-1 Expression in Human Mesangial Cells: Role for JNK/AP-1 Pathway J. Immunol., March 1, 2003; 170(5): 2557 - 2563. [Abstract] [Full Text] [PDF]

				D. Li, T. L. Zimmerman, S. Thevananther, H.-Y. Lee, J. M. Kurie, and S. J. Karpen Interleukin-1beta -mediated Suppression of RXR:RAR Transactivation of the Ntcp Promoter Is JNK-dependent J. Biol. Chem., August 23, 2002; 277(35): 31416 - 31422. [Abstract] [Full Text] [PDF]

<